|
Indications and Dosage
Ophthalmic
Ocular hypertension, Open-angle glaucoma Adult: As 0.01% or 0.03% soln: Instill 1 drop into the affected eye(s) once daily at bedtime. Ophthalmic Hypotrichosis of eyelashes Adult: As 0.03% soln: Apply 1 drop evenly to each eye along the skin of the upper eyelid at the base of eyelashes once daily at bedtime.
|
|
Special Precautions
Patient w/ active intraocular inflammation (e.g. uveitis), aphakic patient, pseudophakic patient w/ torn posterior lens capsule, risk factor for macular oedema; history of herpes simplex, or uveitis/irits. Pregnancy and lactation.
|
|
Adverse Reactions
Ocular pruritus, swelling, irritation and burning sensation; conjunctival hyperaemia, dry eye symptoms, blurred vision, periorbital erythema, increased lacrimation, madarosis, trichorrhex, skin hyperpigmentation and discolouration, growth and darkening of eyelashes, hypersensitivity, rash (including macular, erythematous, and pruritic limited to eyelids and periorbital region); eyelid oedema, irritation and pruritus; periorbital and lid changes resulting in deepening of eyelid sulcus; headache, HTN, abnormal LFT.
|
|
Patient Counseling Information
Remove contact lenses prior to admin and reinsert after 15 min. May cause discolouration of soft contact lenses.
|
|
Monitoring Parameters
Monitor intraocular pressure.
|
|
Drug Interactions
May increase intraocular pressure w/ latanoprost. May reduce therapeutic effect w/ NSAIDs.
|
|
Action
Description:
Mechanism of Action: Bimatoprost, a synthetic prostamide analogue, reduces intraocular pressure by increasing the outflow of aqueous humour. It also increases the percent and duration of hair in the growth phase. Pharmacokinetics: Absorption: Absorbed through the cornea and sclera. Time to peak plasma concentration: W/in 10 min. Distribution: Moderately distributed into body tissues. Volume of distribution: 0.67 L/kg. Plasma protein binding: Approx 88%. Metabolism: Undergoes oxidation, N-deethylation and glucuronidation to form various metabolites. Excretion: Via urine (up to 76%); faeces (25%). Elimination half-life: Approx 45 min. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Bimatoprost, CID=5311027, https://pubchem.ncbi.nlm.nih.gov/compound/Bimatoprost (accessed on Jan. 21, 2020) |
|
Storage
Store between 2-25°C.
|
|
MIMS Class
|
|
ATC Classification
S01EE03 - bimatoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma and hypotrichosis of the eyelashes.
|
|
References
Anon. Bimatoprost and Timolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/01/2015. Buckingham R (ed). Bimatoprost. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/01/2015. Joint Formulary Committee. Bimatoprost. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/01/2015. Latisse Solution Drops (Allergan Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/01/2015. Latisse. U.S. FDA. https://www.fda.gov/. Accessed 28/01/2015. McEvoy GK, Snow EK, Miller J et al (eds). Bimatoprost (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 28/01/2015.
|
Sign Out
